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The microtubule binding affinities of a series of syn-
thetic taxanes have been measured with the aims of
dissecting individual group contributions and obtain-
ing a rationale for the design of novel compounds with
the ability to overcome drug resistance. As previously
observed for epothilones, the positive and negative
contributions of the different substituents to the bind-
ing free energies are cumulative. By combining the
most favorablesubstitutions we increased the binding
affinity of paclitaxel 500-fold. Insight into the structural
basis for this improvement was gained with molecular
modeling and NMR data obtained for microtubule-
bound docetaxel. Taxanes with affinities for microtu-
bules well above their affinities for P-glycoprotein
are shown not to be affected by multidrug resistance.
This finding strongly indicates that optimization of the
ligand-target interaction is a good strategy to over-
come multidrug resistance mediated by efflux pumps.
INTRODUCTION
Cancer is one of the major causes of premature death in humans,
and multidrug resistance (MDR) of neoplastic tissues is a major
obstacle in cancer chemotherapy. Though many tumors initially
respond favorably to chemotherapeutic treatment, effectiveness
at tumor regression is limited by the development of resistance.
Although several primary reasons account for MDR, the predom-
inant cause is the overexpression and drug efflux activity of
several transmembrane proteins, as best exemplified by P-gly-
coprotein (P-gp) (Shabbits et al., 2001).
P-gp is a member of the ATP binding cassette (ABC) family,
with broad substrate specificity for substances, including anti-
cancer drugs, peptides, and HIV protease inhibitors. It has
been shown that the extent of drug resistance in human tumors
correlates well with P-gp expression (Tan et al., 2000).Chemistry & BiologyIn a previous work with a small group of C-2 substituted ceph-
alomannines (CPHs) (Yang et al., 2007), we noticed that the
resistance indexes for high-affinity taxanes in MDR cells are
much lower than those for the medium-affinity taxanes, pacli-
taxel (TXL) and docetaxel (DXL), used in clinical practice. These
results suggest that increasing the binding affinity of these com-
pounds might be an alternative to overcome MDR, the rationale
for this being that affinity for tubulin is the main force driving the
entrance of the ligand into cells.
When MDR cells are exposed to taxanes, two opposite
forces control ligand uptake: (1) binding to P-gp, which pumps
the ligand out of the cell, and (2) binding to tubulin, which re-
duces the intracellular concentration of the ligand and keeps
it bound inside the cell. Thus, the higher the binding affinity of
the ligand for tubulin, the lower the intracellular concentration
of free ligand. Because efflux relies on drug binding to P-gp,
which in turn depends on free ligand concentration, at intracel-
lular ligand concentrations far below its dissociation constant
from P-gp, the efflux will be strongly decreased. In the most
extreme case of a ligand that binds covalently to the taxane
site, such as the natural product cyclostreptin, every molecule
entering the cell will be finally trapped by tubulin, and the tumor
cell’s MDR phenotype will be completely circumvented (Buey
et al., 2007).
Although numerous chemical and biological qualitative stud-
ies of the structure-activity relationships of taxanes have been
performed (Zefirova et al., 2005; Kingston and Newman, 2007),
an in-depth study of the contributions of the different substitu-
ents to the binding thermodynamics has not been conducted.
We have previously shown that for epothilone (EPO) derivatives
(Buey et al., 2004), the thermodynamic contributions of the sub-
stituents are accumulative, that is, the same substitution on
different ligands produces a similar change on the binding affin-
ity. The effect of a single modification can thus be quantified, and
both favorable and unfavorable contributions can be combined
to build tailor-made ligands with the desired affinities.
We now report on the thermodynamics of binding of a set of 44
taxanes (called Chitax [CTX]), plus the three reference com-
pounds, TXL, DXL, and CPH (Figure 1), to crosslinked stabilized15, 573–585, June 2008 ª2008 Elsevier Ltd All rights reserved 573
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Thermodynamics-Driven Design of TaxanesFigure 1. Chemical Structure of the Taxanes Employed in This Studymicrotubules (MT) in order to quantify the contributions of single
modifications at four specific locations of the taxane scaffold:
two of them, C2, in the southern part of the molecule, and C13,
where side chains have been described as essential for taxane
activity (Chen et al., 1993b), and another two, C7 and C10, in
the northern part of the molecule, where substituents have
been shown as nonessential for taxane activity (Chen et al.,
1993a). It is known that the side chains at these positions accept
modifications that modulate the activity, favorably and unfavor-
ably (Ojima et al., 1997; Kingston et al., 1998; Yang et al.,
2007). The activity of these taxanes was investigated against
the parental (A2780) and MDR P-gp-overexpressing (A2780AD)
human ovarian carcinoma cell lines (Rogan et al., 1984). We
were able to correlate the binding affinity of these tubulin
ligands to their cytotoxicity in the resistant cells. Moreover,
the resulting thermodynamic data was used to design novel
high-affinity taxanes with the ability to overcome P-gp-related
resistance. The higher affinity of these newly designed com-
pounds has been rationalized by experimentally determining
the tubulin bound conformation of DXL and by modeling the
complexes of b-tubulin with DXL, TXL, and the best of the
designed taxanes.574 Chemistry & Biology 15, 573–585, June 2008 ª2008 Elsevier LtdRESULTS
Thermodynamics of Binding of TXL Analogs
to Stabilized MTs
All the compounds were first shown to be TXL-like MT-stabilizing
agents (MSA) (see Table S1 available online). Then, their affinity
for the taxane-binding site was measured using the competition
method previously employed (Buey et al., 2004; Table 1 and Ta-
ble S2). Every compound was initially measured using Flutax-2
as the competitor. Compounds 4, 11, 12, 13, 14, 19, 20, and
21 displayed very high affinities, completely displacing Flutax-2
at equimolar concentrations (Figure 2A). This indicated that
they were in the limit of the range of measurement allowed by
the previously employed test (Dı´az and Buey, 2007).
To measure the binding affinity of these compounds more pre-
cisely, we used a direct competition experiment with a higher-
affinity compound, EPO-B, whose binding affinity (7.5 3 108
M1 at 35C) has been previously determined (Buey et al.,
2005; Figure 2B). This allowed the precise determination of the
binding affinities of compounds 4, 11, 12, 13, 14, 19, 20, and
21, whose values range between 1.42 3 108 M1 for the com-
pound with the lowest affinity, CTX-21, and 1.51 3 109 M1 forAll rights reserved
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Thermodynamics-Driven Design of TaxanesTable 1. Apparent Binding Affinities, Thermodynamic Parameters of Binding of Taxanes for the TXL site, 107 M1, and Cytotoxicity of
the Compounds to Nonresistant and Resistant Ovarian Carcinoma Cells
Compound Kb 35C DG 35C kJ/mol DH kJ/mol DS J/mol IC50 A2780 nM IC50 A2780AD nM R/S
TXLa 1.43 ± 0.17 42.1 ± 0.3 51 ± 4 29 ± 13 1.3 ± 0.4 980 ± 149 753
DXLa 3.93 ± 0.27 44.8 ± 0.2 53 ± 2 26 ± 8 0.6 ± 0.2 290 ± 16 483
CPH 0.69 ± 0.08 40.3 ± 0.3 39 ± 6 6 ± 18 1.5 ± 0.2 910 ± 285 606
CTX-1 0.49 ± 0.12 39.4 ± 0.6 56 ± 12 56 ± 39 13.2 ± 7 1222 ± 300 92.5
CTX-2 0.043 ± 0.018 33.2 ± 0.9 66 ± 18 109 ± 38 950 ± 80 10,200 ± 1900 10.7
CTX-3 0.072 ± 0.017 34.5 ± 0.5 32 ± 9 10 ± 29 1250 ± 200 4000 ± 700 3.2
CTX 4b 87 ± 19 52.7 ± 0.5 46 ± 13 19 ± 44 2.7 ± 0.6 14 ± 3.8 5.2
CTX-5 5.37 ± 1.39 45.6 ± 0.6 40 ± 4 19 ± 14 6.6 ± 1.8 160 ± 19 24.2
CTX-6 1.62 ± 0.24 42.5 ± 0.4 39 ± 2 13 ± 7 10 ± 2.4 274 ± 30 27.4
CTX-7 0.39 ± 0.06 38.8 ± 0.4 38 ± 5 4 ± 17 14.5 ± 2.9 2100 ± 660 145
CTX-8 0.492 ± 0.073 39.4 ± 0.3 28 ± 3 39 ± 10 22.5 ± 5 596 ± 105 26.4
CTX-9 0.028 ± 0.008 32.1 ± 0.6 15 ± 4 56 ± 12 3900 ± 370 15,000 ± 3500 3.8
CTX-10 0.042 ± 0.008 33.1 ± 0.4 12 ± 5 68 ± 18 4900 ± 600 >20000 >4
CTX 11b 38 ± 10 50.5 ± 0.6 14 ± 20 117 ± 65 1.36 ± 0.2 163 ± 37 120
CTX 12b 151 ± 3 54.1 ± 0.1 29 ± 9 84 ± 29 2.8 ± 0.38 42 ± 13 15
CTX 13b 16.5 ± 2.8 48.4 ± 0.4 28 ± 1 66 ± 1 1.3 ± 0.2 128 ± 17 98.4
CTX 14b 80.0 ± 2.9 52.5 ± 0.1 46 ± 6 21 ± 19 1.6 ± 0.3 25 ± 10 15.6
CTX-15 2.384 ± 0.53 43.5 ± 0.5 18 ± 11 80 ± 35 17.5 ± 2.7 5250 ± 1000 300
CTX-16 0.050 ± 0.030 33.6 ± 1.2 18 ± 9 49 ± 30 740 ± 100 7360 ± 750 9.9
CTX-17 0.902 ± 0.37 41.0 ± 0.9 24 ± 3 55 ± 10 18 ± 5.6 5412 ± 1200 301
CTX-18 1.281 ± 0.27 41.9 ± 0.5 22 ± 4 64 ± 14 2.1 ± 0.8 452 ± 36 215.2
CTX 19b 14.8 ± 0.2 48.2 ± 0.1 48 ± 3 0 ± 9 0.54 ± 0.07 39 ± 11 72.2
CTX 20b 80.6 ± 5.1 52.5 ± 0.2 92 ± 19 124 ± 64 3.9 ± 1.2 27.4 ± 4 7
CTX 21b 14.2 ± 1.6 48.0 ± 0.3 26 ± 5 72 ± 16 1.9 ± 0.3 41 ± 11 21.5
CTX-22 0.013 ± 0.00 30.1 ± 0.0 46 ± 7 151 ± 23 2400 ± 1000 6960 ± 670 2.9
CTX-23 0.007 ± 0.00 28.6 ± 0.0 37 ± 7 123 ± 22 11,500 ± 1000 23,800 ± 2200 2.1
CTX-24 0.094 ± 0.01 35.2 ± 0.3 65 ± 10 95 ± 33 353 ± 19 8600 ± 3800 24.3
CTX-25 0.008 ± 0.00 28.9 ± 0.0 47 ± 7 154 ± 24 6200 ± 2600 28,500 ± 5300 4.6
CTX-26 0.018 ± 0.00 31.0 ± 0.0 73 ± 11 77 ± 137 3500 ± 1400 8300 ± 2700 2.4
CTX-27 0.007 ± 0.00 28.6 ± 0.0 42 ± 6 138 ± 21 10,000 ± 740 9400 ± 1700 0.94
CTX-28 0.17 ± 0.04 36.7 ± 0.5 17 ± 8 62 ± 25 82 ± 16 1880 ± 200 22.9
CTX-29 0.25 ± 0.08 37.7 ± 0.7 52 ± 9 48 ± 30 102 ± 8.8 690 ± 60 6.8
CTX-30 1.76 ± 0.91 42.7 ± 1.1 11 ± 15 92 ± 49 30 ± 0.5 246 ± 27 8.2
CTX-31 0.10 ± 0.04 35.4 ± 0.9 44 ± 11 30 ± 36 106 ± 4.2 2950 ± 480 27.8
CTX-32 0.24 ± 0.08 37.6 ± 0.7 7 ± 16 87 ± 55 62 ± 17 3200 ± 250 51.6
CTX-33 0.07 ± 0.01 34.4 ± 0.3 81 ± 12 152 ± 39 69 ± 77 1500 ± 100 21.7
CTX-34 1.20 ± 0.93 41.7 ± 1.5 38 ± 28 14 ± 94 28.7 ± 1.9 196 ± 14 6.8
CTX 35 0.88 ± 0.77 40.9 ± 1.6 29 ± 33 13 ± 112 25 ± 2 153 ± 39 6.12
CTX 36 0.029 ± 0.020 32.2 ± 1.3 48 ± 6 63 ± 18 1700 ± 120 >20000 >11.7
CTX 37 0.035 ± 0.010 32.7 ± 0.6 91 ± 7 207 ± 24 86 ± 9.8 10,000 ± 1000 116.2
CTX 38 0.001 ± 0.001 23.6 ± 1.8 44 ± 9 70 ± 34 15,400 ± 3200 20,000 ± 3000 1.3
CTX 39 0.003 ± 0.001 26.4 ± 0.7 157 ± 10 461 ± 28 4200 ± 100 5700 ± 300 1.3
CTX 40b 628 ± 15 57.7 ± 0.1 26 ± 24 99 ± 80 7 ± 1 9.1 ± 0.45 1.3
CTX 41 0.021 ± 0.004 31.4 ± 0.4 94 ± 9 202 ± 28 14,000 ± 2000 >20000 1.4
CTX 42 0.008 ± 0.003 28.9 ± 0.8 106 ± 13 250 ± 43 192 ± 20 2750 ± 430 14.3
CTX 43 0.030 ± 0.008 32.3 ± 0.6 85 ± 20 169 ± 66 69.5 ± 3.8 331 ± 70 4.8
CTX 44 0.001 ± 0.001 23.6 ± 1.8 177 ± 23 493 ± 75 >20,000 >20,000
Errors are standard errors of the mean.
a Binding affinity and thermodynamic parameters data are from Buey et al. (2004).
b Compounds measured with the EPO-B displacing method.Chemistry & Biology 15, 573–585, June 2008 ª2008 Elsevier Ltd All rights reserved 575
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Thermodynamics-Driven Design of Taxanesthe highest-affinity compound, CTX-12. This method was vali-
dated when the binding affinities of compounds 11, 13, 19,
and 21 (those in the range of 108 M1) were shown to be similar
using either EPO-B or Flutax-2 (see the Supplemental Data).
To confirm that the high affinity of compounds containing 3-N3
benzoyl at C2 does not originate from covalent binding of its
reactive azido group to b-tubulin, we performed experiments in
Figure 2. Binding of the Ligands to the Paclitaxel Site
(A) Displacement of the fluorescent taxane Flutax-2 bound to MT sites (50 nM)
by taxanes at 35C. The solid lines were generated with the best-fit value of the
binding equilibrium constant of the competitors with binding affinities lower to
107 M1, assuming a one-to-one binding to the same site. Additional lines
(dashed) show the expected displacement for ligands with binding constants
of 108 M1 (black), 109 M1 (red), 1010 M1 (green), and 1011 M1 (yellow).
Ligands binding data are as follows: green CPH, red CTX-2, yellow CTX-6,
dark blue CTX-11, magenta CTX-12, light blue CTX-14, black CTX-27.
(B) Displacement of EPO-B bound to MT sites (10 mM) by CTX-40 at 35C. One
micromolar TXL-binding sites were incubated with 1.1 mM EPO-B (black lines)
or with 1.1 mM EPO-B and 1.1 mM CTX-40 (red lines), MTs were harvested by
sedimentation, ligands extracted from supernatants (solid lines) and pellets
(dashed lines), and HPLC analyzed. One micromolar TXL was used as the
internal standard. Supernatant traces were displaced 40 mAU for presentation
purposes.576 Chemistry & Biology 15, 573–585, June 2008 ª2008 Elsevier Ltdwhich the amounts of reversibly bound compounds 4, 12, and
14 were measured. The bound compounds could be extracted
from the pellets and aqueous solutions with the aid of an organic
solvent, indicating that they are not irreversibly bound.
Molecular Modeling
One conspicuous characteristic of the taxane-binding site in b-
tubulin (Lowe et al., 2001) is the presence of the highly exposed
side chain of His229 (located in the middle of helix 7 and posi-
tionally equivalent to Arg229 in a-tubulin) that splits the cavity
into two major pockets. Because continuum electrostatic calcu-
lations predicted the imidazole ring of this residue to be doubly
protonated at pH 6.5 (pKHis229 = 7.2), this ionization state was
used in subsequent work.
Molecular dynamics (MD) studies of TXL, DXL, and CTX-40
in aqueous solution provided us with a range of different
conformers, the most abundant of which (Figure S1) were inde-
pendently studied in a first rigid-body approach by the auto-
mated docking program. The conformation previously reported
for TXL (Lowe et al., 2001; Snyder et al., 2001) using either
DOCK or FlexX was also found by AutoDock among the best
scoring solutions. Because similar poses were found for DXL
(Figure S2) and CTX-40 as well, this common disposition of the
taxane in the binding site of b-tubulin was used in the modeling
of all the complexes. Noteworthy is that these conformations are
not the most populated in aqueous solution (data not shown)
although they are sporadically observed in the course of transi-
tions toward other more stable and ‘‘hydrophobically collapsed’’
conformations. The proposed docked conformation for TXL is
then coincident with that previously found in crystals of 7-mesyl-
paclitaxel, which was reportedly induced by specific interactions
of the side chain at C13 with solvent (Gao and Chen, 1996).
The feasibility of the resulting modeled complexes was
assessed by subjecting each of them to a 10 ns MD simulation
followed by a simulated annealing procedure that provided us
with a set of representative complex structures for further analy-
sis and energy decomposition. In all cases, the ligand adopts
a conformation in good agreement with the T-taxol geometry
(Snyder et al., 2001; Figure 3) and is anchored in the binding
site through a common set of well-defined interactions. Thus,
the oxetane oxygen of the taxane is engaged in a good hydrogen
bond with the NH of Thr276, whereas another hydrogen bond is
established between the amide or carbamate carbonyl oxygen
on the C13 substituent and the N3 of His229. The common phe-
nyl ring at C13 (30-Ph) establishes close van der Waals contacts
with the hydrophobic side chains of Val23 and Ala233, whereas
the benzoyl phenyl ring at C2 (2-OBz) gets lodged into another
hydrophobic cavity, on the other side of His229, made up of
the side chains of Leu217, Leu219, and Leu275. The offset
stacking interaction of this latter phenyl with the imidazole ring
of His229 (Figure S3) is improved by the substituent at the
meta position whose 1,2- (methoxy, CTX-13) or 1,3-dipole
(azide, CTX-40) additionally establishes a favorable electrostatic
interaction with the amide dipole of the backbone peptide bond
between His229 and Leu230 (Figure 3). Of the three hydroxyl
groups that are common to the four ligands studied, that present
on the C13 substituent is consistently engaged in a hydrogen
bonding interaction with the carboxylate of Asp26 in helix 1
and the backbone nitrogen of Arg369, whereas that at C7 canAll rights reserved
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Thermodynamics-Driven Design of TaxanesFigure 3. Model of the Ligands Bound to the
Paclitaxel Site
(A) TXL and (B) CTX-40 in the binding site of b-
tubulin at the end of the simulated annealing pro-
cedure. Note that the doubly protonated imidazole
ring of His229 participates in (1) a hydrogen bond-
ing interaction with the amide or carbamate car-
bonyl oxygen on the C13 substituent through the
N3, and (2) an offset stacking interaction with the
phenyl ring on the C2 substituent.establish transient hydrogen bonds with the carboxamide group
of Gln282. The hydroxyl at C1 is permanently exposed to the
solvent.
The four complexes yielded very low RMS deviations for the
protein atoms with respect to the refined b-tubulin-TXL structure
1JFF (1.3 A˚ on average for 400 atoms). The major differences
when compared with this particular complex are the presence
of a different rotameric state for His229, which we propose is
protonated at physiological pH, and improved stacking and
hydrogen bonding interactions between the ligand and the pro-
tein as a consequence of the mutual adaptation resulting from
the simulated annealing procedure.
NMR Characterization of Bound Docetaxel
As a further step, and to provide empirical support for the mod-
eling-derived conformations that formed the basis for the quest
of the structure-activity relationship, the MT-bound conforma-
tion of DXL was elucidated, under the experimental conditions
used for determining the binding constants (see the Supplemen-
tal Data file DXLNMR.pdb).
As previously shown, the transferred nuclear Overhauser en-
hancement (TR-NOESY) technique provides an adequate means
to determine the bound conformation of ligands that exchange
between free and bound states at a reasonably fast rate. TR-
NOESY experiments were then performed on the DXL:MT sample
at different mixing times. Negative crosspeaks were clearly ob-
served at 310 K (Figures 4A and 4B), as expected for a ligand
that binds to the assembled MTs preparation, in contrast with
the lack of NOEs detected in the free state (Figure 4C).
Two control experiments were performed employing either
Flutax-2 instead of DXL (the effective koff of Flutax-2 release
from MTs is 1.63 ± 0.18 s1 (Diaz et al., 2000) or both DXL and
discodermolide (DDM) at equimolecular concentrations. No
TR-NOESY signals were observed in the presence of Flutax-2,
indicating that the effective koff of DXL is higher than that previ-
ously measured for Flutax-2, and the DXL signals were cancelled
out by DDM (whose affinity for the TXL-binding site is 1003
higher), indicating that DXL is effectively bound to the TXL site
(Buey et al., 2005).
Cytotoxicity in Resistant and Nonresistant Tumor Cells
To check the effects of the studied modifications on the cytotox-
icities of the compounds and to validate the binding affinity ap-Chemistry & Biologyproach as a tool to be used in ligand optimization, we performed
IC50 tests in A2780 human ovarian carcinoma cells and their
MDR A2780AD counterparts (Table 1 and Figure 5A).
The cytotoxicities of the ligands in non-P-gp-overexpressing
A2780 cells show a linear relationship (r = 0.81) with their binding
affinities, but only for those compounds with a DG at 35C higher
than 47.5 kJ/mol1 (Kb at 35C higher than 108 M1), which
points to a limit in the cytotoxicity that can be achieved. Thus,
despite the increase in affinity of three orders of magnitude
between CPH and CTX-40, the IC50 remained in the order of
nanomolar.
In the case of the MDR A2780AD cells, a good linear relation-
ship (r = 0.80) between cytotoxicities and binding affinities is
observed for the full set of ligands, strongly suggesting that for
these P-gp-overexpressing cells, tubulin binding is the main
force competing with P-gp-mediated extrusion.
The best regression lines have slopes of 1.10 for A2780 cells
and 0.61 for A2780AD cells, which indicates that P-gp-overex-
pression effectively reduces the intracellular drug concentration,
thus making it necessary to increase the load to exert a cytotoxic
effect.
Intake of Taxanes by Tumor Cells
The amount of compound made available for binding to the tubu-
lin site was measured by employing radioactively labeled DXL
and TXL at the concentrations needed to stop the cell cycle in
G2/M, in two leukemic cell lines (U937 and K562) and the kidney
epithelial nontumor cell line PtK2 from Potorus tridactylis. In
these conditions, the intracellular drug concentration, which
ranges from 0.3 to 2.8 mM and represents a small percentage
of the total drug and the cell tubulin concentrations (Table S3),
increases with the total drug concentration and reaches a maxi-
mum in PtK2 cells at 300 nM DXL and 600 nM TXL. The equilibra-
tion of the ligand inside the cells is fast, with a half-life of 3 min for
14C-DXL and 10 min for 3H-TXL at a drug concentration of 1 mM.
The drug inside the cell was found to be in the cytoplasm, with
only a small fraction bound to the nucleus, as expected.
Because the total intracellular drug concentration is more than
one order of magnitude above its MT dissociation constant and
much lower than the total tubulin concentration (which was con-
sidered to be 5% of the total protein measured), the mass
action law dictates that most of the compound inside the cells
is essentially bound to tubulin and the intracellular concentration15, 573–585, June 2008 ª2008 Elsevier Ltd All rights reserved 577
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Thermodynamics-Driven Design of TaxanesFigure 4. NMR Characterization of the Prerelease Conformation of Bound Docetaxel
(A) The 500 MHz TR-NOESY (mixing 200 ms, 310 K) spectrum of DXL in buffered water solution in the presence of MTs (20:1 molar ratio).
(B) Expansion showing the key TR-NOESY region: close contacts between the tert-butyl chain and the aromatic 2-OBz ring (besides the trivial crosspeaks with
the vicinal 30-Ph moiety).
(C) The NOESY experiment under the same experimental conditions (200 ms) in the absence of MTs did not show any crosspeak. (D) Expansion of the aromatic
region in the TR-NOESY spectrum; no NOEs between the two aromatic 30-Ph and 2-OBz moieties are observed.of free drug is close to the dissociation constant (i.e., 70 nM for
TXL and 25 nM for DXL).
DISCUSSION
The effects of modifications on the substituents attached to the
baccatin scaffold on the cytotoxicity of taxanes have been qual-
itatively discussed in several reviews (Zefirova et al., 2005; King-
ston and Newman, 2007). However, the fact that these studies
were performed in different cell lines precludes a rigorous evalu-
ation of the relationship between structural changes and
cytotoxicity. To quantify the effects of substitutions at a set of
specific positions in a systematic way, the binding affinity for
the taxane-binding site on b-tubulin has proved to be a more pre-
cise and objective parameter (Buey et al., 2004).
With all the binding constants determined at a given tempera-
ture (35C), it has been possible to determine the changes in ap-578 Chemistry & Biology 15, 573–585, June 2008 ª2008 Elsevier Ltdparent binding free energy caused by single-group modifications
(Table 2) and to select the most favorable substituents at the
positions chosen for optimization. Once this knowledge was ob-
tained, it became feasible to design several optimized taxanes.
Effect on Binding Affinity of Changes at the C2 Position
C2 modifications have proven to be the most effective in modu-
lating the activity of taxanes. Thus, the 2-OBz is essential as its
removal (Chen et al., 1993b) or replacement with other small
side chains (Ojima et al., 1994; Nicolaou et al., 1995) results in
almost total loss of activity in the human colon cancer cell line
tested. In contrast, changes in the structure of the ring, including
its replacement with nonaromatic or heterocyclic rings, result in
only moderate losses of antitumor activity (Ojima et al., 1994).
Introduction of substituents on the 2-OBz ring, (Nicolaou et al.,
1994; Kingston et al., 1998; Yang et al., 2007) results in increases
of activity for small groups at the meta position but loss of activityAll rights reserved
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Thermodynamics-Driven Design of Taxanesfor the other positions. Changes in the linker connecting the ben-
zene ring to the taxane core also result in decreased biological
activity (Wang et al., 2007).
Our results confirm and extend the qualitative data summa-
rized above and provide a precise quantitative characterization
of the effects of C2 modifications on binding affinity:
(a) Changing the nature of the linker between the benzene ring
and the taxane scaffold results in a large loss of binding free
energy. Thus, the replacement of the ester by an ether, thio-
ether, or amine moiety (compounds 24, 25, 26, 27, 38, and 39)
or by a thioester or an amide (compounds 22, 23, 42, 43, and
Figure 5. Comparison between Binding Affinity and Cytotoxicity in
A2780 and A2780AD Cells
(A) Dependence of the IC50 of the ligands against A2780 (black) and A2780AD
(gray) human ovarian carcinoma cells on the affinity for the TXL-binding site in
MTs (binding constant, Kb). The black line represents the best fit of IC50 against
A2780 cells versus binding affinity for ligands with binding affinity under 5 3
108 M1. The gray line represents the best fit of IC50 against A2780AD cells ver-
sus binding affinity.
(B) Dependence of the resistance index of the A2780AD MDR cells on the af-
finity of the compounds for the taxane binding site. The range of binding affin-
ities of taxanes for P-gp was taken from Yang et al. (2007).Chemistry & Biology44) results in a heavy loss of binding free energy (up to 20 kJ/
mol1). This stringent requirement indicates that the angle
between the benzyl ring and the taxane core has to be strictly
preserved and must be related to steric hindrance, as previ-
ously discussed for the thiobenzoyl compounds 22 and 23
(Wang et al., 2007), because the analogs in which the benzyl
group is replaced by an alkyl ester (compounds 2, 3, 9, 10,
and 16) only display a moderate loss of binding free energy
(5–6 kJ/mol1), which can be assigned to the loss of interac-
tions between the benzyl ring and the binding site.
(b) Modification of the meta substituents on the benzyl ring
leads to gains of binding free energy that are the largest for
N3 (11.2 ± 1.1 kJ/mol1) and OCH3 (7.2 ± 0.6 kJ/
mol1) groups (compounds 4, 5, 11, 12, 13, 14, 20) and
much smaller (2–3 kJ/mol1) for halogen atoms (com-
pounds 6, 30, and 34), whereas other small groups (CN
and CH3) have no effect (compounds 7 and 8). Other simi-
larly small substitutions (OH and CH2OH; compounds
36 and 37) are detrimental, resulting in a loss of 7–9 kJ/
mol1 of binding free energy.
(c) Introduction of double substituents at the 2,4 (compounds
28, 29) and 2,5 (35) positions results in loss of binding affinity.
(d) The thienoyl moiety (compounds 31 and 32) can effectively
replace the benzoyl group.
Because previous work from our group (Buey et al., 2004) has
shown that substitutions leading to gains in binding free energy
also give rise to increased cytotoxicity, the N3 substituent at
the meta position of 2-OBz was selected as the most suitable
for molecule optimization.
Effect on Binding Affinity of Changes at the C13 Position
The side chains present at position C13 in one semisynthetic
(DXL) and two natural taxanes (CPH and TXL) were evaluated
to choose the optimal one for binding. Although from the direct
comparison of TXL and DXL alone (Diaz and Andreu, 1993) it is
not possible to assess the effect of the C13 side chain on the
binding free energy due to the presence of additional differences
in the substituents at C7 and C10, DXL showed a 1.9-fold larger
binding affinity relative to TXL, which corresponds to a change
of 1.6 kJ/mol1 in free energy of binding. A similar difference
(23) was observed in the cytotoxicity on 1A9 cells (Buey et al.,
2005). In contrast, the tubulin binding affinity and the cytotoxicity
of CPH are about 23 lower than those of DXL (Yang et al., 2007).
In our series, by comparing compounds TXL, DXL, CPH, 11,
12, 13, 14, 15, 17, 20, 21, 22, 23, 24, 25, 26, 27, 38, 39, and
40, differing only in the side chain at C13 present in the reference
molecules, we can now establish that, of the three side chains,
DXL provides the largest contribution to the binding free energy,
(DDG C13-DXLC13-TXL = 3.2 ± 0.9 kJ/mol1, DDG C13-
CPHC13-DXL = 5.6 ± 1.1 kJ/mol1).
Effect on Binding Affinity of the Substituents Present
in the Northern Side of the Taxane Ring (C7 and C10)
Modifications on the northern face of TXL at positions C7 and
C10 have little effect on tubulin binding, as expected from the
previously described effects on cytotoxicity (Chen et al.,
1993a). From all the substituents tested at C10, the best one
turns out to be the propionyl group, which provides an15, 573–585, June 2008 ª2008 Elsevier Ltd All rights reserved 579
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Modification Type Modification Compounds DDG Avg (Std Err)
C2 Benzoyl/ benzylether T/ 25 +13.2 +13.0 ± 0.2
21/ 24 +12.8
Benzoyl/ benzylsulphur T/ 27 +13.6 +15.9 ± 2.3
21/ 26 +18.1
Benzoyl/ benzylamine T/ 38 +18.6 +20.1 ± 1.5
21/ 39 +21.6
Benzoyl/ thiobenzoyl T/ 23 +19.6 +15.9 ± 3.8
21/ 22 +12.1
Benzoyl/ benzamide 21/ 42 +19.2
Benzamide/ 3-OCH3-benzamide 42/ 43 3.4
Benzamide/ 3-Clbenzamide 42/ 44 +5.3
Benzoyl/ 3-methyl- 2 butenoyl 1/ 2 +6.2
Benzoyl/ 3-methyl- 3 butenoyl 1/ 3 +4.9
Benzoyl/ 2(E)-butenoyl 1/ 9 +7.3
Benzoyl/ 3-methyl- butanoyl 1/ 10 +6.3
Benzoyl/ 2-debenzoyl-1,2-carbonate C/ 16 +5.8
Benzoyl/ 3-N3 Benzoyl 1/ 4 8.0 11.2 ± 1.3
T/ 12 13.9
C/ 14 12.2
18/ 20 10.6
Benzoyl/ 3-OCH3-benzoyl 1/ 5 6.2 7.2 ± 0.6
T/ 11 8.3
C/ 13 8.1
18/ 19 6.3
Benzoyl/ 3-Clbenzoyl 1/ 6 3.1
Benzoyl/ 3-Br-benzoyl 1/ 34 2.3
Benzoyl/ 3-I-benzoyl 1/ 30 3.3
Benzoyl/ 3-NC-benzoyl 1/ 7 +0.6
Benzoyl/ 3-CH3-benzoyl 1/ 8 0.0
Benzoyl/ 3-CH2OH-benzoyl 1/ 36 +7.2
Benzoyl/ 3-OH-benzoyl 18/ 37 +9.2
3-ClBenzoyl/ 2,4-di-Clbenzoyl 6/ 29 +4.8
Benzoyl/ 2,4-di-F-benzoyl 1/ 28 +2.7
3-OCH3-Benzoyl/ 2-5-di- OCH3-benzoyl 5/ 35 +4.6
Benzoyl/ 2-thienoyl 1/ 31 +4.1
Benzoyl/ 3-thienoyl 1/ 32 +1.8
Benzoyl/ 6-carboxy-pyran-2-one 1/ 41 +8.1
C13 Side Chain TXL/ CPH T/ C +1.9 +2.0 ± 0.2
11/ 13 +1.9
12/ 14 +1.6
15/ 17 +2.4
TXL/ DXL 23/ 22 1.7 3.2 ± 0.9
25/ 24 6.2
27/ 26 1.3
38/ 39 2.8
T/ 21 4.2
CPH/ DXL C/ 21 3.8 5.6 ± 1.1
17/ D 7.7
20/ 40 5.2
C10 Acetyl/ –OH T/ 15 1.3 1.7 ± 0.8580 Chemistry & Biology 15, 573–585, June 2008 ª2008 Elsevier Ltd All rights reserved
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Modification Type Modification Compounds DDG Avg (Std Err)
C/ 17 0.7
21/ D 3.2
Propionyl/ –OH 18/ 17 +0.9 +0.9
Acetyl/ propionyl C/ 18 1.6 0.5 ± 0.4
13/ 19 +0.2
14/ 20 0.0
C7 Propionyl/ –OH 17/ 1 1.6 1.6
Errors are standard errors of the mean.incremental free energy change of around 0.5 kJ/mol1 over
the natural C10 acetyl. In contrast, introduction of the same
group at position C7 brings about a loss of 1.6 kJ/mol1 of bind-
ing free energy relative to the OH present in TXL. For this rea-
son, a propionyl at C10 and a hydroxyl at C7 were selected as
optimal substituents at these positions.
Optimal Taxane
According to the data measured, the optimal taxane should have
DXL’s side chain at C13, an m-N3-benzoyl at C2, a propionyl at
C10, and a hydroxyl at C7. Starting from compound 1, the first
one in the series, with an apparent binding affinity of 39.4 kJ/
mol1, the resulting molecule should gain 5.6 kJ/mol1 from
the replacement of the CPH side chain with that of DXL, 11.2
kJ/mol1 from the substitution of m-N3-benzoyl for benzoyl at
C2, 1.6 kJ/mol1 from the change of a propionyl at C7 to a hy-
droxyl, and 0.9 kJ/mol1 from the change of a hydroxyl at C10
to a propionyl. Taking all of these changes together, the optimal
taxane would have a predicted DG at 35C of 58.7 kJ/mol1.
When the compound was synthesized (CTX-40) and its binding
affinity was measured using the EPO-B displacement method
(Kb 35
C = 6.28 ± 0.15 3 109 M1; DG = 57.7 ± 0.1 kJ/
mol1), the experimental value was found to be in good corre-
spondence with the predicted value.
Structural Interpretation of the Binding Data
Two different reasons have been proposed for the changes in
activity due to modifications at C2: (1) the need for a hydrophobic
group to maintain the proper taxane conformation or (2) direct
interactions of the benzoyl with hydrophobic side chains of the
protein (Zefirova et al., 2005). The modeling data support the
view that the higher affinity of CTX-40 relative to TXL and DXL,
which is mostly conferred by the phenylazide substituent present
at C2, may largely stem from the simultaneous improvement of
the stacking interactions with the imidazole ring of His229(+)
and a better electrostatic interaction with Asp26 and Arg369
on the opposite side of the molecule, resulting from a better
anchoring of the ligand in the binding site. The same rationale
applies to CTX-13, which has a methoxy substituent in place of
the azide, and to a lesser extent to the derivatives containing
halogen atoms. As regards the methyl, cyano, hydroxyl, or hy-
droxymethyl substituents, they are likely to be found facing the
solvent rather than orientated toward the binding pocket, thus
contributing negligibly to the binding affinity, in good accord
with the experimental evidence.Chemistry & BiologyLikewise, the enhanced affinity contribution of the DXL
and CTX-40 side-chain at C13 relative to that of TXL arises
from an improved hydrogen-bonding interaction of the car-
bamate NH relative to the amide NH with the carboxylate
of Asp26.
Prerelease Conformation of Bound Docetaxel
Transferred NOESY signals arise from a free DXL molecule
whose protons have been excited when still bound to the protein
but relaxed after release from the binding site. Thus, the confor-
mation deduced from these signals corresponds to a prerelease
state of the ligand. It has been described that MT-stabilizing
agents binding to the TXL site reach their luminal final location
through prior transient binding to a site located in the MT pore
(Diaz et al., 2003; Buey et al., 2007). Therefore the NMR struc-
tural data have to be interpreted with this caution.
Because DXT release from MT following excitation has to be
fast in order to get trNOESY signals, the Koff of the ligand should
be fast in the relaxation time scale. This is apparently in contradic-
tion with the slow dissociation constant measured for TXL in
a kinetic study, 0.091 ± 0.006 s1 (Diaz et al., 2003). This observed
dissociation constant does not correspond to the release step
but to the rate-limiting step of the reaction. The dissociation of
taxanes from MT has been studied in detail using the fluorescent
taxane derivatives Flutax-1 and Flutax-2, which dissociate from
MT following a two-step mechanism (Diaz et al., 2000). The first
step, which is the slower one (thus the one directly observed),
has a kinetic rate constant of 0.022 ± 0.001 s1 (4-fold slower
than that of TXL), whereas the second one (responsible for the re-
lease of the ligand to the medium and which can be measured
only indirectly from the dependence of the kinetic rate constants
on concentration) is nearly 100 times faster (koff = 1.63 ± 0.18 s
1).
In the absence of the fluorescent probe it is not possible to cal-
culate the value of the kinetic rate constant of the release step of
DXL dissociation (koff). Control experiments with Flutax-2 per-
formed in the same conditions did not show any trNOESY signal
from this ligand, which indicates that its koff value is not large
enough to provide good trNOESY signals. Therefore, the effec-
tive kinetic rate of the release step of the dissociation process
of DXL has to be higher. Because it is not unreasonable to think
that the presence of the fluorescein moiety slows down the dis-
sociation of Flutax-2 and the observed trNOESY crosspeaks for
the DXL:MT ensemble are cancelled out by addition of DDM
(a TXL-binding site ligand with a much higher affinity (Buey
et al., 2005), it can be assumed that the detected signals arise15, 573–585, June 2008 ª2008 Elsevier Ltd All rights reserved 581
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may be bound to either the external site or to a modified luminal
site.
The basic features of the NMR-derived conformation might be
extracted from the trNOESY crosspeaks. Clear NOEs are
observed between the t-butyl protons and the 2-OBz protons
(Figure 4B), whereas only extremely weak NOEs are observed
between both aromatic (2-OBz and 30-Ph) moieties (Figure 4D).
The OAc-4 group also provides NOEs with both aromatic rings
(Figure 4B). These experimental observations allow us to discard
the presence of the so-called ‘‘polar conformation’’ for DXL when
this molecule is bound to MT. The NMR-derived conformation is
thus basically in agreement with the conformation derived from
the modeling approach (see Figure S4). And though the modeled
structure is in agreement with the so-called ‘‘T-taxol geometry’’
(Snyder et al., 2001), the NMR-derived conformation is interme-
diate between this one and that dubbed collapsed geometry
(Vandervelde et al., 1993). That both conformations are fairly
similar and resemble the T-taxol conformation possibly indicates
that the prerelease step does not largely affect the conformation
of DXL, and that the T-taxol conformation is stable in the protein
environment. The only observed difference is likely due to the
presence of His229, which in the modeled structure is found be-
tween the 2-OBz and the C13 side chain, thus further separating
these two moieties. The NMR observations are in agreement
with a closer proximity between the OBz and the t-Bu protons
(4–5 A˚) than that suggested by the modeled DXL-b-tubulin
complex (5–6 A˚). Under these constraints, the NMR-deduced
prerelease bound geometry for DXL, which is close to that
of T-taxol, is in agreement with that derived by the modeling pro-
cedure and resembles that described for the tubulin-bound
conformation of TXL (Lowe et al., 2001), though the experimental
conditions herein are markedly different.
Binding Affinity, Cytotoxicity and P-gp-Overexpression-
Mediated Multidrug Resistance
The double-log plots representing cytotoxicity versus tubulin
binding affinity (Figure 5A) clearly indicate that, as in the case
of EPOs and other taxane-binding site ligands, both magnitudes
are related, with the binding affinity behaving as a good predictor
of cytotoxicity. However, a deviation from the predicted behavior
can be noted from this data. There is an apparent cytotoxicity
limit (IC50 = 1 nM) for these compounds against the non–P-gp-
overexpressing cells. A review of the results from our earlier
work (Buey et al., 2004, 2005) indicates that there are no MSA
with an IC50 below nM in these cells. Despite having binding con-
stants of the order of 109 M1, DDM and several EPOs have IC50s
in the order of 1 nM or higher. In fact, cis-CP-tmt-EPO-B (com-
pound 19 in Buey et al. [2004]), the compound with the highest
affinity for the TXL-binding site so far described (2.1 3 1010
M1), and also the most cytotoxic (IC50 = 0.1 nM), displays a bind-
ing affinity three orders of magnitude above that of TXL but only
a 10-fold increase in cytotoxicity (Buey et al., 2004). These data
suggest that a significant percentage of tubulin within the cell has
to be bound to stop the cell cycle; cytotoxicity is thereby limited
by the amount of compound that is needed to achieve this goal.
At the drug concentrations required to stop cell-cycle progres-
sion, the percentage of tubulin bound by the ligand is in the range
of 2%–20% of the whole available protein. In the drug intake582 Chemistry & Biology 15, 573–585, June 2008 ª2008 Elsevier Ltdexperiments, the total amount of compound available at the
concentrations needed to stop the cell cycle (or at the IC50) is
around one-third (comparable) of the total amount of tubulin. Al-
though this should be enough, in principle, for binding to a signif-
icant percentage of the protein, the results indicate that the
amount of ligand available for binding to the sites is effectively
much smaller (2%–10%). The reason for this might be that
though all the binding sites are inside the small volume occupied
by the cells, the drugs have to pass through the cell membranes
and reach a threshold intracellular concentration that is opposed
by the detoxification pumps. If a significant percentage (say 2%–
5%) of cytoplasmic tubulin has to be bound for the taxane to
exert its cytotoxicity, and the amount of ligand available for pro-
tein binding is a small percentage (2%–10%) of the total 1 nM
concentrations—which is already one-third of the total amount
of tubulin in the cells—it follows that for the MSA with a taxane
way of action the 0.1–1 nM concentration is a limit for its cytotox-
icity in cells. The same reasoning can be applied to a systemically
distributed drug for which the minimal amount needed to kill
the tumor cells is related to the amount of tubulin available for
binding, which imposes a practical limit on the lowest dose
that can be used.
However, if the goal is not to find a drug with the highest
cytotoxicity possible (none of the newly synthesized high-affinity
compounds has a remarkably better cytotoxicity on nonresistant
cells than TXL and DXL) but rather to find one with the ability
to overcome the main problem appearing in patients undergoing
treatment with MSA—namely P-gp-mediated resistance—at-
tempts to increase the affinity would seem to be steps in the right
direction. Cells overexpressing P-gp are still sensitive to taxanes
because they can still be killed by higher concentrations of either
TXL or DXL. These very high concentrations affect normal
nontumor cells as well, causing them to be differentially killed
because of their inability to reduce the intracellular drug concen-
tration, rather than differentially spared because of their lower
division rate.
The data with A2780AD cells shows the expected correlation
(although with a lower slope arising from their ability to reduce
the intracellular drug concentration) between affinity and cyto-
toxicity that was previously observed for chemically related
compounds (Buey et al., 2004) with no deviations being noted
at the highest cytotoxicity values (9 nM for CTX-40). In this
type of MDR cells the high-affinity drugs are nearly 100-fold
more cytotoxic than the clinically employed taxanes (TXL and
DXL) and display very low resistance indexes (as low as 1.3
for the highest-affinity derivative, CTX-40). This result was
confirmed with LoVo human colon carcinoma cells and their
MDR LoVo-Dox counterparts (Grandi et al., 1986; see the Sup-
plemental Data).
When the resistance indexes of the compounds are repre-
sented against their binding affinities (Figure 5B), a bell-shaped
curve is observed: the resistance index shows a maximum for
taxanes displaying similar affinities for tubulin and P-gp, and
then rapidly decreases when the affinity of the compound for tu-
bulin either increases or decreases. An exception to this rule is
found for compounds having a halogen atom (or a methoxy
group) at the meta position of 2-OBz (CTX-5, 6, 30, 34, and 35)
as they exhibit a much lower resistance index than that of other
compounds with equivalent affinity.All rights reserved
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ligands or with covalent binders (which can be considered to
have infinite affinity) whose cytotoxicity is unaffected by P-gp
overexpression (e.g., DDM: IC50 values of 60 nM and 53 nM
[I. Barasoain, unpublished data] or cyclostreptin: IC50 values of
43.5 nM and 51 nM [Buey et al., 2007]) against A2780 and
A2780AD cells, respectively, which is a clear indication that li-
gands with high affinity for the taxane-binding site can overcome
the P-gp-mediated MDR phenotype. The rationale for this find-
ing is that, in these cells, the intracellular free concentration of
the high-affinity binding drugs will be low (see Figures S5–S7
for a detailed mathematical model). It is clear that for the ligand
to be pumped out it first has to bind to P-gp, and assuming
that the kinetics of drug efflux follows a Michaelis-Menten
behavior, the ligand outflow will decrease with lower free ligand
concentration. Because these ligands are tightly bound to tubu-
lin, their intracellular free concentrations are of the order of their
dissociation constants, which in the case of the high-affinity
compounds (Kd of CTX-40 = 0.16 nM at 35
C) are far below their
dissociation constants from P-gp (which range between 35 nM
for TXL and 88 nM for CTX-7; Yang et al., 2007). This implies
that, at concentrations able to exert cytotoxicity, the efficacy
of P-gp to pump out the high-affinity compounds will be reduced
by a factor between 200 and 1,000 (see the Supplemental Data).
From a chemical standpoint, P-gp overexpression is irrelevant.
However, the low-affinity tubulin-binding ligands may escape
the effect of the pump through a different mechanism. Because
they need to reach concentrations that are much higher than
those of either tubulin or P-gp to bind their target and thereby ex-
ert their cytotoxicity, the pump gets overloaded (saturated) and
cannot effectively reduce the intracellular drug concentration.
For this reason, these ligands act as MDR reversal agents by
themselves (Brooks et al., 2003).
The present findings support the view (Buey et al., 2004, 2005)
that binding affinity is the main variable to be maximized in at-
tempts to increase the cytotoxicity of this type of compound (al-
though on nonresistant cells a practical limit is observed at around
1 nM concentration). Additionally, high-affinity compounds can
escape MDR due to P-gp overexpression by lowering the con-
centration of free ligand that can be pumped out by P-gp.
SIGNIFICANCE
The binding affinities of a series of synthetic taxanes forMTs
have been measured with the aims of dissecting individual
group contributions and obtaining a rationale for the design
of novel compounds with the ability to overcome drug resis-
tance. As previously observed for EPOs, the positive and
negative contributions of the different substituents to the
binding free energy are cumulative. By combining the most
favorable substitutions in a single analog, the binding affinity
was increased 500-fold over that of TXL. Insight into the
structural basis for this improvement was gained when
models were built that assigned an important role to the in-
teractions of C2 and C13 substituents with the protonated
side chain of His229. The relative orientation of these groups
was found to be in agreement with NMR data obtained for
MT-bound DXL.Chemistry & BiologThe cytotoxicities of the compounds in ovarian carcinoma
A2780 cells were found to correlate with their affinities, with
an apparent cytotoxicity limit in the nanomolar range. A bell-
shaped curve was obtained when the taxane resistance in-
dex was plotted versus the binding affinity showing that
the P-gp-overexpressing multidrug-resistant A2780AD cells
are sensitive to the highest and lowest affinity compounds,
whereas resistance indexes in the range of 100 to 1,000
were obtained for those whose binding affinities for tubulin
and P-gp are similar.
The finding that taxanes with affinities for MTs well above
their affinities for P-gp are not affected by multidrug resis-
tance strongly indicates that for a series of compounds
with similar pharmacokinetic and bioavailability properties,
optimization of the ligand-target interaction is a good strat-
egy to overcome multidrug resistance mediated by efflux
pumps.
EXPERIMENTAL PROCEDURES
Proteins and Ligands
Purified calf brain tubulin and chemicals were as described (Diaz and Andreu,
1993). Full details of the synthesis and characterization of the ligands em-
ployed can be found in the Supplemental Data.
Ligand-Induced Tubulin Assembly
Critical concentrations of ligand-induced tubulin assembly were measured as
described (Buey et al., 2005).
Equilibrium Binding Constants of the Ligands to MTs and Tubulin
The binding constants of the ligands with apparent binding affinities below 108
M1 for the TXL-binding site were measured as described (Buey et al., 2004).
For the EPO-B method, samples of 1 ml containing 1 mM sites in glutaralde-
hyde-stabilized MTs, 1.1 mM EPO-B and 1.1 mM of the test compound in
GAB (glycerol assembly buffer; 3.4 M glycerol, 10 mM sodium phosphate,
6 mM MgCl2, and 1 mM EGTA [pH 6.7]) with 0.1 mM GTP were incubated
for 30 min at 35C in polycarbonate centrifuge tubes (Beckman Coulter, Inc.,
Fullerton, CA). The samples were then centrifuged at 90,000 3 g for 20 min
at 35C in a TLA-100.2 rotor employing a Beckman Optima TLX ultracentri-
fuge. The supernatants were collected by pipetting, and the pellets were re-
suspended in 10 mM phosphate buffer (pH 7.0). One micromolar TXL was
added as the internal standard, except for the experiments with CTX-13 in
which 1 mM DXL was used instead. Both the pellets and the supernatants
were extracted three times with an excess volume of dichloromethane, dried
in vacuum, and dissolved in 35 ml of methanol. The samples were analyzed
by HPLC.
Reversibility of binding was checked by incubating samples containing 5 mM
compounds 4, 12, or 14, and 10mM taxoid binding sites in stabilized crosslinked
MT for 30 min at 25C in polycarbonate centrifuge tubes (Beckman) in GAB with
0.1 mM GTP (DMSO concentration was always kept under 2%). The samples
were then centrifuged at 90,000 g for 10 min at 25C in a Beckman Optima
TLX ultracentrifuge with a TLA100 rotor, processed, and analyzed as described.
Binding constants for compounds reversibly displacing Flutax-2 or EPO-B
were calculated using Equigra v5 (Dı´az and Buey, 2007). The thermodynamic
parameters (apparent DG0, DH0, and DS0) were calculated as described (Buey
et al., 2005).
Binding of the compounds to unassembled dimeric tubulin was measured
by centrifugation. Two hundred microliter samples containing 20 mM tubulin
and 25 mM compound in 10 mM phosphate, 1 mM EDTA (pH 7.0) buffer
(PEDTA) containing 1 mM GDP were incubated for 1 hr at 35C in polycarbon-
ate centrifuge tubes (Beckman). The samples were then centrifuged at
386,000 3 g for 1 hr at 35C in a TLA100 rotor employing a Beckman Optima
TLX ultracentrifuge. The upper and lower 100 ml of the solution were carefully
collected by pipetting, and the pellets were resuspended in 10 mM phosphate
buffer (pH 7.0). The tubulin concentrations in the three samples werey 15, 573–585, June 2008 ª2008 Elsevier Ltd All rights reserved 583
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standard. The samples were extracted and analyzed as described.
HPLC analysis of all samples was performed in an Agilent 1100 series instru-
ment employing a Supercosil, LC18 DB, 250 3 4.6 mm, 5 mm bead diameter
column developed in a gradient from 50% to 80% (v/v) acetonitrile in water at
a flow rate of 1 ml/min1, following the absorbance at l = 220 nm.
Cell Biology Studies
PtK2 (kidney epitelial cell from Potorus tridactylis), U937 (monocytic human
leukemia), K562 (myelocytic human leukemia), A2780, P-gp-overexpressing
A2780AD (ovarian carcinoma) cells were cultured as described previously
(Buey et al., 2005). Cytotoxicity assays were performed with the MTT assay
modified as described in Yang et al. (2007).
Cell intake of 3H-TXL and 14C-DXL were measured as reported (Manfredi
et al., 1982) with modifications, using PtK2, U937, and K562 cells. These cells,
and especially the PtK2 cells, were used because they are more resistant to
taxanes, and more reproducible results could be obtained. Cells were grown
in 24-well plates at a density of 500,000 cells/ml (PtK2) or 300,000 cells/ml (leu-
kemic cell lines) and were incubated in 1 ml of medium with the desired drug
concentration. Supernatants were collected, and cells were washed three
times with 1 ml of cold PBS and incubated overnight with 0.25 ml of NaOH
0.1M, and then neutralized with 0.25 ml of HCl 0.1 M. The total protein concen-
tration was determined by the Lowry method and the drug (both in the super-
natants and incorporated into cells) was measured by liquid scintillation count-
ing in a LKB 1219 spectrometer (GE Healthcare Bio-Sciences, Uppsala,
Sweden). The correction for unspecific binding was determined by measuring
the amount incorporated in cells preincubated with 10 mM colchicine for 4 hr at
37C and washed three times prior to the incubation with 3H-TXL or 14C-DXL.
Cell volume was calculated from the volume occupied by the pellets and found
to be 2.5 ± 0.2, 3.96 ± 0.05, and 4.3 ± 0.9 mL/106 cells for U937, K562, and
PtK2, respectively.
The amounts of drugs bound to the nucleus and cytoplasm of the cells were
determined as described in Simpson et al. (1987).
Molecular Modeling
The refined structure of the a,b-tubulin dimer at 3.5 A˚ resolution (Lowe et al.,
2001; Protein Data Bank code: 1JFF) was used for molecular modeling and li-
gand docking. Addition of missing hydrogen atoms and computation of the
protonation state of ionizable groups in b-tubulin at pH 6.5 were carried out us-
ing the H++ Web server (Gordon et al., 2005), which relies on AMBER (Cornell
et al., 1995) force-field parameters and finite difference solutions to the Pois-
son-Boltzmann equation. The molecular graphics program PyMOL (DeLano
Scientific, LLC, Palo Alto, CA) was employed for molecular visualization and
representation. The charge distribution for the ligands studied was obtained
by fitting the quantum mechanically calculated (RHF 6-31G*\\3-21G*) molec-
ular electrostatic potential (MEP) to a point charge model, as implemented in
Gaussian 03 (Gaussian, Inc., Wallingford, CT). Consistent bonded and non-
bonded AMBER parameters were assigned to ligand atoms in the taxanes
by analogy or through interpolation from those already present in the AMBER
database (ff03).
The Lamarckian genetic algorithm implemented in AutoDock 3.0.5 (Morris
et al., 1998) was used to generate automated docked poses of TXL, DXL,
CTX-13, and CTX-40 within the taxane-binding site by randomly changing
the overall orientation of conformers from the MD ensembles that were repre-
sentative of the major populations, as well as the torsion angle involving the
2-OBz.
NMR Experiments
The NMR experiments were performed at 310 K in D2O as described (Jimenez-
Barbero et al., 2006), with modifications described in the Supplemental Data,
on a Bruker AVANCE 500 spectrometer (Bruker, Bruker BioSpin GmbH, Rhein-
stetten, Germany).
SUPPLEMENTAL DATA
Supplemental Data include seven figures, three tables, Supplemental Experi-
mental Procedures, Supplemental References, and two additional Supple-584 Chemistry & Biology 15, 573–585, June 2008 ª2008 Elsevier Ltdmental Data files and can be found with this article online at http://www.
chembiol.com/cgi/content/full/15/6/573/DC1/.
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